
News|Articles|November 13, 2017
Pfizer Appoints New COO
Author(s)Pharmaceutical Technology Editors
The company has appointed Albert Bourla, PhD, as its new COO.
Advertisement
Pfizer announced on Nov. 13, 2017 that it appointed Albert Bourla, PhD, as its new COO, effective Jan. 1, 2018.
Since early 2016, Dr. Bourla has been the group president of Pfizer’s innovative health business, and has held a range of senior global positions. He holds a PhD degree in the biotechnology of reproduction from the Veterinary School of Aristotle University.
“The naming of a chief operating officer comes at a time when our business is strong as we continue to advance our strategy while also managing a dynamic and challenging external environment, said Ian Read, Pfizer chairman and CEO.
Source:
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why Oral Solid Dosage Validation Is a Business Continuity Function, Not Just a Compliance Requirement
2
Technology Transfer: Success Drivers and Obstacles Explained
3
Managing Global Trial Supply Risk: Expert Insights
4
How to Vet Importer of Record Partners for Clinical Trials
5




